Table 1.
Respondents’ baseline characteristics
| Characteristics | Overall |
| N (%) | 165 (100) |
| Male (%) | 121 (73.3) |
| Training: interventionalist (%) | 84 (50.9) |
| Geography (%) | |
| North America | 23 (13.9) |
| South America | 2 (1.2) |
| Europe | 112 (67.9) |
| Africa | 1 (0.6) |
| Middle East | 2 (1.2) |
| Asia | 10 (6.1) |
| Australia | 15 (9.1) |
| Appointment level (%) | |
| Junior | 11 (6.7) |
| Mid-career | 28 (17.0) |
| Senior | 126 (76.4) |
| Annual mechanical thrombectomy volume (%) | |
| <100 | 50 (30.3) |
| 100–200 | 66 (40.0) |
| >200–300 | 29 (17.6) |
| >300 | 20 (12.1) |
| Dedicated stroke patient care time (%) | |
| <10% | 10 (6.1) |
| 10–50% | 77 (46.7) |
| 51–99% | 63 (38.2) |
| 100% | 15 (9.1) |
| Acceptable uncertainty margin (%), median (IQR)) | 3 (1–5) |
| Trial participation (%) | |
| IVT vs placebo: yes (%) | 42 (25.5) |
| MT+IVT vs IVT: yes (%) | 51 (30.9) |
| MT vs MT +IVT= :yes (%) | 51 (30.9) |
| In patients undergoing MT do you stop IVT before full dose is administered? (%) | |
| No, unless there are clear medical reasons (eg, angiographic signs of bleeding) | 102 (61.8) |
| Yes, as a standard procedure at first device deployment | 16 (9.7) |
| Yes, as a standard procedure after successful reperfusion is reached | 7 (4.2) |
| Yes, on an individual case basis after successful reperfusion is reached | 31 (18.8) |
| Other | 9 (5.5) |
Data are displayed as n (%), and median (IQR).
IVT, intravenous thrombolysis; MT, mechanical thrombectomy.